RT Journal Article
SR Electronic
T1 Diversity in Parkinson’s disease genetics research: current landscape and future directions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21266995
DO 10.1101/2021.12.07.21266995
A1 Artur F. Schumacher-Schuh
A1 Andrei Bieger
A1 Olaitan Okunoye
A1 Kin Mok
A1 Shen-Yang Lim
A1 Soraya Bardien
A1 Azlina Ahmad Annuar
A1 Bruno Lopes-Santos
A1 Matheus Zschornack Strelow
A1 Mohamed Salama
A1 Shilpa C Rao
A1 Yared Zenebe Zewde
A1 Saiesha Dindayal
A1 Jihan Azar
A1 LK Prashanth
A1 Roopa Rajan
A1 Alastair J Noyce
A1 Njideka Okubadejo
A1 Mie Rizig
A1 Suzanne Lesage
A1 Ignacio Mata
A1 On behalf of the Global Parkinson’s Genetics Program (GP2)
YR 2021
UL http://medrxiv.org/content/early/2021/12/08/2021.12.07.21266995.abstract
AB Human genetics research lacks diversity; over 80% of genome-wide association studies (GWAS) have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine. This systematic review provides an overview of research involving Parkinson’s disease (PD) genetics in under-represented populations (URP), and sets a baseline to measure the future impact of current efforts in those populations.We searched PubMed and EMBASE until October 2021 using search strings for “PD”, “genetics”, the main “URP”, and “lower-to-upper-middle-income countries”. Inclusion criteria were original studies, written in English, reporting genetic results on PD patients from non-European populations. Two levels of independent reviewers identified and extracted relevant information.We observed considerable imbalances in PD genetic studies among URP. Asian participants from China were described in the majority of the articles published (61%), but other populations were less well studied, for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just seven studies using a genome-wide approach published up to 2021 including URP.This review provides insight into the significant lack of population diversity in PD research highlighting the urgent need for better representation. The Global Parkinson’s Genetics Program (GP2) and similar initiatives aim to impact research in URP, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Global Parkinson's Genetics Program (GP2) is a resource project from the Aligning Science Across Parkinson's (ASAP) initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors